Cargando…

The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs

The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use, launched in Berlin during the Correlation Hepatitis C Initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Schatz, Eberhard, Schiffer, Katrin, Maher, Mags, Harris, Magdalena, Roca, Xavier Major, Maticic, Mojca, Leicht, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918866/
https://www.ncbi.nlm.nih.gov/pubmed/30288317
http://dx.doi.org/10.1186/s41124-016-0021-9
_version_ 1783317509219287040
author Schatz, Eberhard
Schiffer, Katrin
Maher, Mags
Harris, Magdalena
Roca, Xavier Major
Maticic, Mojca
Leicht, Astrid
author_facet Schatz, Eberhard
Schiffer, Katrin
Maher, Mags
Harris, Magdalena
Roca, Xavier Major
Maticic, Mojca
Leicht, Astrid
author_sort Schatz, Eberhard
collection PubMed
description The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use, launched in Berlin during the Correlation Hepatitis C Initiative conference in October 2014, was formulated and endorsed by many key organizations in the hepatitis field. The Manifesto takes strides to pinpoint shortcomings in hepatitis action oriented towards the population most affected by the hepatitis C virus (HCV): active drug users. Despite a considerable amount of evidence that active drug users are disproportionately affected by HCV, barriers to care remain. Engagement with representatives of communities of people who inject drugs (PWID) is imperative in order to effectively create guidelines which reflect reality. Unfortunately, widespread systemic stigmatization and lack of trust between affected communities, decision-makers and healthcare professionals have reproduced this divide. The Berlin Manifesto has identified a disconnect between evidence and action which must be answered. In this roundtable discussion, experts from diverse parts of the hepatitis community have contributed their perspectives and experience on access to prevention, testing, and treatment for HCV in PWID. The authors discuss relevant topics such as realities of access to HCV treatment in the United Kingdom, interventions of a regional network of active drug users in Europe and lack of PWID involvement in government policy in Catalonia. Collectively they challenge the neglect of HCV in PWID by many decision-makers and health care professionals and promote a scale-up of integrated prevention and treatment strategies focusing on this population. The authors’ conclusions aim to clarify the discourse on hepatitis in order to prevent disease, save lives and work towards eventual hepatitis elimination.
format Online
Article
Text
id pubmed-5918866
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59188662018-10-04 The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs Schatz, Eberhard Schiffer, Katrin Maher, Mags Harris, Magdalena Roca, Xavier Major Maticic, Mojca Leicht, Astrid Hepatol Med Policy Debate The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use, launched in Berlin during the Correlation Hepatitis C Initiative conference in October 2014, was formulated and endorsed by many key organizations in the hepatitis field. The Manifesto takes strides to pinpoint shortcomings in hepatitis action oriented towards the population most affected by the hepatitis C virus (HCV): active drug users. Despite a considerable amount of evidence that active drug users are disproportionately affected by HCV, barriers to care remain. Engagement with representatives of communities of people who inject drugs (PWID) is imperative in order to effectively create guidelines which reflect reality. Unfortunately, widespread systemic stigmatization and lack of trust between affected communities, decision-makers and healthcare professionals have reproduced this divide. The Berlin Manifesto has identified a disconnect between evidence and action which must be answered. In this roundtable discussion, experts from diverse parts of the hepatitis community have contributed their perspectives and experience on access to prevention, testing, and treatment for HCV in PWID. The authors discuss relevant topics such as realities of access to HCV treatment in the United Kingdom, interventions of a regional network of active drug users in Europe and lack of PWID involvement in government policy in Catalonia. Collectively they challenge the neglect of HCV in PWID by many decision-makers and health care professionals and promote a scale-up of integrated prevention and treatment strategies focusing on this population. The authors’ conclusions aim to clarify the discourse on hepatitis in order to prevent disease, save lives and work towards eventual hepatitis elimination. BioMed Central 2016-10-18 /pmc/articles/PMC5918866/ /pubmed/30288317 http://dx.doi.org/10.1186/s41124-016-0021-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Schatz, Eberhard
Schiffer, Katrin
Maher, Mags
Harris, Magdalena
Roca, Xavier Major
Maticic, Mojca
Leicht, Astrid
The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title_full The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title_fullStr The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title_full_unstemmed The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title_short The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
title_sort berlin hepatitis c manifesto: access to prevention, testing, treatment and care for people who use drugs
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918866/
https://www.ncbi.nlm.nih.gov/pubmed/30288317
http://dx.doi.org/10.1186/s41124-016-0021-9
work_keys_str_mv AT schatzeberhard theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT schifferkatrin theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT mahermags theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT harrismagdalena theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT rocaxaviermajor theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT maticicmojca theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT leichtastrid theberlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT schatzeberhard berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT schifferkatrin berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT mahermags berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT harrismagdalena berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT rocaxaviermajor berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT maticicmojca berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs
AT leichtastrid berlinhepatitiscmanifestoaccesstopreventiontestingtreatmentandcareforpeoplewhousedrugs